# NIH Reporter #5R43AI192105-02

Optimizing immunogenicity of novel Cryptosporidium vaccine candidates

**Recipient:** IMMPORT THERAPEUTICS, INC.

**Award Amount:** $300,000.00
**Ceiling:** $300,000.00

**Awarded:** September 14, 2026

**Identifier:** 5R43AI192105-02

Development of a novel vaccine candidate for cryptosporidiosis by testing recombinant Cryptosporidium proteins with an adjuvant to stimulate immune responses in preclinical models.

### Description

This project aims to formulate and test novel Cryptosporidium proteins combined with a potent adjuvant to stimulate mucosal and systemic immune responses. The study involves producing recombinant proteins, formulating vaccines with GLA-3M052 liposome adjuvant, and evaluating immunogenicity and protective efficacy in mouse models. The goal is to develop a vaccine candidate suitable for preclinical testing.

[View original record](https://reporter.nih.gov/search/IgE1H2ioLUOz0qmA4MDg0Q/project-details/11392430)